Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04730999 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer(CeLEBrATE) | completed | Phase 2 | 54 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 |
| clinicaltrials |
| NCT01513174 | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone(GOAL) | completed | Phase 1 / Phase 2 | 186 | Spanish Lung Cancer GroupOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02200757 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | completed | Phase 2 | 135 | ImmunityBio, Inc.INDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT03693300 | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 117 | AstraZenecaINDUSTRY | 6 | Jun 18, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03847519 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 24 | Advaxis, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03497767 | A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases(OUTRUN) | completed | Phase 2 | 40 | Trans Tasman Radiation Oncology GroupOTHER | 2 | May 31, 2024 | clinicaltrials |
| NCT03022500 | Pulmonary sarcomatoid_MEDI4736+Treme | completed | Phase 2 | 32 | Seoul National University HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04426825 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 23 | Hoffmann-La RocheINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT03001882 | An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate 592) | completed | Phase 2 | 230 | Bristol-Myers SquibbINDUSTRY | 8 | May 20, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT03810066 | Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) | completed | Phase 2 | 16 | University Hospital, EssenOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | completed | Phase 1 / Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT01928576 | Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.(NA_00084192) | completed | Phase 2 | 143 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02658097 | Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03146962 | High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies | completed | Phase 2 | 61 | Weill Medical College of Cornell UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04381910 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | completed | Phase 2 | 66 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02118415 | Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) | completed | Phase 2 | 13 | Technical University of MunichOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03861156 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | completed | Phase 2 | 290 | InventisBio Co., LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03958097 | Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer | completed | Phase 2 | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02581787 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 28 | Maximilian DiehnOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02337530 | Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | completed | Phase 2 | 62 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 21, 2024 | clinicaltrials |
| NCT02414139 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) | completed | Phase 2 | 373 | Novartis PharmaceuticalsINDUSTRY | 20 | Mar 20, 2024 | clinicaltrials |
| NCT04212052 | Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT02247349 | BMS-986012 in Relapsed/Refractory SCLC | completed | Phase 1 / Phase 2 | 106 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 5, 2024 | clinicaltrials |
| NCT00020202 | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03976518 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)(CHANCE) | completed | Phase 2 | 43 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04238169 | Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | completed | Phase 2 | 60 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT03360630 | Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC | completed | Phase 1 / Phase 2 | 60 | Capital Medical UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT04577638 | Accelerated Radio-Immunotherapy for Lung Cancer(AIRING) | completed | Phase 2 | 8 | Center Eugene MarquisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01542437 | Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 66 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer(PAINT) | completed | Phase 2 | 35 | Albert Einstein College of MedicineOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study(NSCLC) | completed | Phase 1 / Phase 2 | 21 | Humanetics CorporationINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03087760 | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | completed | Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer(RAMP202) | completed | Phase 2 | 90 | Verastem, Inc.INDUSTRY | 5 | Jan 12, 2024 | clinicaltrials |
| NCT02709720 | Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC(NORA) | completed | Phase 2 | 68 | Spanish Lung Cancer GroupOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02581943 | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | completed | Phase 2 | 43 | Wake Forest University Health SciencesOTHER | 1 | Jan 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 5, 2024source: clinicaltrials